

French National Agency for Medicines and Health Products Safety

Report No: **16MPP005NCS**

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer¹

Part 1

Issued following an inspection in accordance with :

Art. 111(7) of Directive 2001/83/EC as amended

Art. 80(7) of Directive 2001/82/EC as amended

The competent authority of France confirms the following:

The manufacturer: ***Anuh Pharma LTD***

Site address: ***E-17/3 & E 17/4 M.I.D.C., Tarapur, Thane District, Boisar, Maharashtra, 401 506, India***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-02-12** , it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC and Article 51 of Directive 2001/82/EC .

¹ The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

Part 2

1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.17 Other: active substance(en)

Manufacture of active substance. Names of substances subject to non-compliant :

ERYTHROMYCIN ETHYLSUCCINATE(en) / ÉRYTHROMYCINE (ÉTHYLSUCCINATE D')(fr)

3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : ERYTHROMYCIN ETHYLSUCCINATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance 3.1.4 Other : starting from erythromycin thiocyanate
3.5	General Finishing Steps
	3.5.1 Physical processing steps : milling, sieving, (micronisation) 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

4. Non-Compliant Other Activities - Active Substances :

The NCR applies to all active substances of the site. List of other active substances manufactured on the site (as communicated by the company - non exhaustive list): Ambroxol Hydrochloride, Azithromycin, Chloramphenicol, Chloramphenicol Palmitate, Ciprofloxacin HCl, Clarithromycin, Erythromycin, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Stearate, Losartan Potassium, Piperaquine phosphate, Pyrazinamide, Roxythromycin, Sulfadoxine.

Part 3

1. Nature of non-compliance:

Overall, 24 deficiencies were observed during the inspection, 1 Critical and 2 Major deficiencies: * * * [Critical 1] No transfer of information to the user of the active substance as regards to the original manufacturers of the active substances only micronized at the site (i.e. manufacturer name, original batch number and COA) and exported to Europe or that may be sold to distributors exporting to Europe. The following active substances were micronized from other sources (as communicated by the company - may not be exhaustive): Azithromycin, Chloramphenicol, Chloramphenicol Palmitate, Ciprofloxacin HCl, Clarithromycin, Piperazine phosphate, Roxithromycin and Sulfadoxine. Moreover, a non EU-GMP compliant source for Azithromycin (NCF/010/RO, Hebei Dongfeng Pharmaceutical Co., Ltd, China) was micronized and directly exported to Europe under the manufacturer name Anuh Pharma. * * * [Major 1] Deficiencies in documentation management. Several documents were found within a pile of rubble on the other side of a wall. These included an original batch repacking record which should have been placed under retention and a large number of purchase orders dated from 2013 for active substances, notably Azithromycin, Chloramphenicol, Chloramphenicol Palmitate, Roxithromycin and Ciprofloxacin HCl. * * * [Major 2] Deficiencies in process validation. No validation data was available for the blending of micronized batches. No cleaning validation was available for one air jet mill used for micronization. No supporting data for the reduced testing of the recovered Ethyl Acetate solvent was available.

Action taken/proposed by the NCA**Withdrawal, of current valid GMP certificate No. IT /E/GMP/9/2013**

Using QRM principles, consideration of withdrawal of current valid EU GMP certificate issued by the Agenzia Italiana del Farmaco (IT/E/GMP/9/2013).

Requested Variation of the marketing authorisation(s)

Using QRM principles, use of an alternate manufacturer should be considered.

Recall of batches already released

Using QRM principles, recall of products should be considered. The risk / benefit ratio for the patients has to be assessed by NCAs to prevent shortage of critical products.

Prohibition of supply

The site has been issued a statement of non compliance and active substances manufactured by the site should not be used for the manufacturing of medicinal products. The risk / benefit ratio for the patients has to be assessed by NCAs to prevent shortage of critical products.

Suspension or voiding of CEP (action to be taken by EDQM)

This inspection was carried out as part of the EDQM inspection programme. The impact of this NCR on the CEPs is to be decided by the EDQM. The concerned CEPs are : CEP 2007-235 (Erythromycin Ethylsuccinate), CEP 2005-059 (Pyrazinamide), CEP 2005-205 (Erythromycin).

Additional comments

The findings reveal a critical non-compliance of the quality system of the company as a whole. Moreover, due to the severe lack of transparency of the company regarding its manufacturing activities, there is no assurance as regards to the origin of every batch of active substances claimed to have been manufactured by the company at the Boisar site. Consequently, it is considered that the identified risks are applicable to all active substances manufactured at the site.

2016-03-24

Name and signature of the authorised person of the
Competent Authority of France

Confidential
French National Agency for Medicines and Health
Products Safety
Tel: ***Confidential***
Fax: ***Confidential***